Rate My Professor Olivia Sanders

Olivia Sanders is a Clinical Research Nurse in the Department of Paediatrics at the University of Otago, Christchurch, within the Division of Health Sciences. She also serves as a Paediatric Diabetes Clinical Nurse Specialist. Her professional activities center on clinical research in paediatric type 1 diabetes management, with a focus on innovative technologies such as open-source automated insulin delivery systems and intensive care protocols implemented from diagnosis. Sanders contributes to multidisciplinary teams advancing diabetes care for children and young people.

Sanders is a co-author on several key publications that have influenced the field of paediatric endocrinology. These include the landmark study 'Open-source automated insulin delivery in type 1 diabetes' published in the New England Journal of Medicine in 2023, part of the CREATE trial evaluating the efficacy of open-source AID systems like AndroidAPS; 'Interviews with Indigenous Māori with type 1 diabetes using open-source automated insulin delivery: a qualitative study' in the Journal of Diabetes & Metabolic Disorders in 2023, which explored patient experiences and barriers for Māori; 'Intensive management from diagnosis improves HbA1c at 12 months post-diagnosis: results from a prospective cohort study in children and young people with type 1 diabetes' in the New Zealand Medical Journal in 2024; 'Learning challenges of healthcare professionals supporting people using open-source automated insulin delivery' in Diabetic Medicine in 2022; 'Impact of Advanced Hybrid Closed Loop on Youth With High-Risk HbA1c Levels' in Diabetes Care in 2023; and 'Glucose and Psychosocial Outcomes 12 Months Following Initiation of Open-Source Automated Insulin Delivery: The CREATE Trial' in Diabetes Technology & Therapeutics in 2024. Her involvement in these studies highlights contributions to improving glycemic control, reducing care burden, addressing healthcare professional training needs, and promoting equitable access to advanced diabetes technologies, particularly for underserved populations in New Zealand.